Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose

Liang, Jennifer L.; Wallace, Greg; Mootrey, Gina T.

doi:10.15585/mmwr.mm6434a5

Cited by 3 publications

(2 citation statements)

References 5 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FDA-approved age indication for use of DTaP vaccines differs, depending upon the specific DTaP product ( Table 4 ). Data on immunogenicity and safety of DTaP vaccines have been published ( 3 , 88 – 94 ).…”

Section: Vaccines For Prevention Of Pertussis Tetanus and Diphtherimentioning

confidence: 99%

“…Quadracel (Sanofi Pasteur) (DTaP-IPV): The immunogenicity of all antigens in Quadracel (diphtheria and tetanus toxoids; pertussis antigens; and inactivated poliovirus types 1, 2, and 3) was noninferior between groups (DTaP-IPV and separately administered DTaP [Daptacel] and IPV [IPOL, Sanofi Pasteur] vaccines) with or without a co-administered second dose of MMR and varicella vaccines ( 94 ).…”

Section: Vaccines For Prevention Of Pertussis Tetanus and Diphtherimentioning

confidence: 99%

See 1 more Smart Citation

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

et al. 2018

View full text Add to dashboard Cite

SummaryThis report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of tetanus, diphtheria, and pertussis in the United States. As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations and replaces all previously published reports and policy notes; it is intended for use by clinicians and public health providers as a resource. ACIP recommends routine vaccination for tetanus, diphtheria, and pertussis. Infants and young children are recommended to receive a 5-dose series of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines, with one adolescent booster dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Adults who have never received Tdap also are recommended to receive a booster dose of Tdap. Women are recommended to receive a dose of Tdap during each pregnancy, which should be administered from 27 through 36 weeks’ gestation, regardless of previous receipt of Tdap. After receipt of Tdap, adolescents and adults are recommended to receive a booster tetanus and diphtheria toxoids (Td) vaccine every 10 years to assure ongoing protection against tetanus and diphtheria.

show abstract

Section: Vaccines For Prevention Of Pertussis Tetanus and Diphtherimentioning

confidence: 99%

Section: Vaccines For Prevention Of Pertussis Tetanus and Diphtherimentioning

confidence: 99%

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

et al. 2018

View full text Add to dashboard Cite

show abstract

Immune persistence after pertussis vaccination

Chen

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Pertussis is one of the most prevalent vaccine-preventable diseases worldwide. The true infection rate is significantly higher than the reported incidence rate. An increased prevalence of pertussis in older populations has been found, mainly caused by waning immunity after vaccination. Vaccine-induced immunity differs due to variation in vaccine content, schedule and coverage. Protection following acellular pertussis vaccines has been suggested to wane faster than whole cell pertussis vaccines. However, long-term immune persistence of whole cell pertussis vaccines may be confounded by a progressive acquisition of natural immunity. The World Health Organization has recommended that a switch from whole cell to acellular pertussis vaccines for primary immunization in infants should only be considered if additional periodic boosters or maternal immunization can be ensured and sustained in the national immunization schedules. In this review, we present data on immune persistence after different pertussis vaccinations and compare the findings from countries with different vaccination strategies. Future aspects in serological studies are briefly discussed.

show abstract

Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4–6 Years of Age

Smith

Jordanov

Sheng

et al. 2017

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose

Cited by 3 publications

References 5 publications

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Immune persistence after pertussis vaccination

Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4–6 Years of Age

Contact Info

Product

Resources

About